NOVEL QUATERNARY AMMONIUM SALTS AND USE THEREOF AS MEDICINE

Abstract: Quaternary ammonium salts represented by general formula (I) and use thereof as medicines, wherein R¹ and R² represent lower alkyl groups which may be the same or different from each other; R³ represents hydrogen, lower alkyl, etc.; A represents lower alkyl, etc.; Q⁻ represents an anion; X represents (a), (b), etc.; Y represents methylene, oxygen or sulfur; Z represents (c), etc.; l and m represent each an integer of 1 or 2; and n represents an integer of 1 to 3.

Description: The present invention relates to novel quaternary ammonium salts and said salts for use as medicines. Conventionally, trimebutine maleate has been primarily used as a gastroprokinetic agent. Trimebutine maleate has wide utility due to its dual activities of promoting and suppressing the gastric contractions. However, it is not necessarily satisfactory in that relatively high dose, i.e., 300 mg per day is required, and that adverse side effects are involved. Therefore, studies have been conducted in search for gastroprokinetic agents which can replace trimebutine maleate (Japanese Patent Application Laid-open (kokai) No. 163074/1991). However, the results have not necessarily been successful in providing gastroprokinetics. Accordingly, development of drugs which possess much stronger activity in enhancement of gastrointestinal motility has still been desired. J. Org. Chem., Vol. 51, pages 730 to 732 describes the compound 1-oxo-1-[(2-(((((5-trimethylammonio)methyl)-2-furanyl)methyl)thio)ethyl)amino]-2-nitroethene (V). The present invention provides novel quaternary ammonium salts represented by the following formula (I): wherein R 1 and R 2 represent alkyl groups having 1 to 5 carbon atoms which may be the same or different from each other; R 3 represents hydrogen, alkyl having 1 to 5 carbon atoms, phenyl, benzyl, or -COOR 4 (wherein R 4 represents alkyl having 1 to 5 carbon atoms); A represents alkyl having 1 to 5 carbon atoms, alkenyl having 2 to 5 carbon atoms, alkynyl having 2 to 5 carbon atoms, -(CH 2 ) p -COOR 5 (wherein R 5 represents hydrogen or alkyl having 1 to 5 carbon atoms, and p represents an integer of from 1 to 5), (wherein R 6 represents hydrogen, hydroxyl, nitro, alkyl having 1 to 5 carbon atoms, -COOR 5 , or -SO 3 R 5 ); Q - represents a counter anion of quaternary ammonium salt; X represents Y represents methylene, oxygen or sulfur; Z represents (wherein R 7 and R 8 are the same or different from each other and independently represent hydrogen, halogen, nitro, alkyl having 1 to 5 carbon atoms, or lower alkoxyl, and R 9 represents alkyl having 1 to 5 carbon atoms, or phenyl); l and m represent each an integer of 1 or 2; and n represents an integer of from 1 to 3, and said salts for use as medicines. Since the compounds according to the present invention have an activity of accelerating the gastrointestinal contractions, i.e., they improve the gastrointestinal motility remarkably, as well as high safety, they have utility in the medical field of treating the gastrointestinal disorders. Examples of alkyl groups having 1 to 5 carbon atoms include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl and tert-pentyl. Examples of alkenyl groups having 2 to 5 carbon atoms include vinyl, allyl, butenyl and 3-methyl-2-butenyl. Examples of alkynyl groups having 2 to 5 carbon atoms include ethynyl and propargyl. Examples of the counter anion of quaternary ammonium salt include fluorine ion, chlorine ion, bromine ion, iodine ion, HSO 4 - , ClO 3 - , NO 3 - , cyanide ion, HSO 3 - ion, IO 3 - ion, HCO 2 - , CH 3 CO 2 - , OH - , phenolate ion, methanesulfonate ion, and toluenesulfonate ion. The compound (I) of the present invention is prepared, for example, by the following reaction scheme: Method A (wherein R 1 , R 2 , R 3 , A, Q, X, Y, Z, l, m and n have the same meaning as defined hereinbefore). That is, compound (I) is obtained by reacting compound (II) which is obtainable by applying a known method (Japanese Patent Application Laid-open (kokai) No. 40956/1983; Japanese Patent Application Laid-open (kokai) No. 91980/1982; R. Soc. Chem., 42, Regul. Biol. Mech., 45-47, 1982) with compound (III). The above reaction is preferably carried out in an inert solvent such as methanol, ethanol, dichloromethane, chloroform, ethyl acetate, dimethylformamide, dimethylsulfoxide and water, in a temperature range of 0°C to a reflux temperature. It is preferred that the compounds (II) and (III) be used in an equimolar amount, or one be used in a slightly larger amount than the other. The reaction time is desirably varied according to the progress and condition of the reaction. Alternatively, the compound (I) of the present invention may be prepared according to the following reaction scheme: Method B (wherein R 1 , R 2 , R 3 , A, X, Y, Z, l, m and n have the same meaning as defined hereinbefore, E represents a protective group for an alcohol such as benzoyl and acetyl, B represents a halogen atom, and D represents a halogen atom or an active ester residue). That is, compound (I) of the present invention is obtained by reacting a halogen compound or an ester compound (IX) with an amine compound (X). The reaction for synthesizing the compound (VI) is preferably carried out in an anhydrous organic solvent, especially under stream of an inert gas such as argon. The reaction temperature is preferably within the range of 0°C to a boiling point, and more preferably, at room temperature. The reaction for synthesizing the compound (VIII) is carried out in the presence of an alkali such as KOH, NaOH and the like, during which the protective group is removed. In the reaction for synthesizing the compound (IX), an organic base may be added if desired. Preferable examples of the agent for halogenation include phosphorus oxychloride. Preferable examples of the acid halide include methanesulfonic acid chloride and toluenesulfonic acid chloride. The compound (I) of the present invention has excellent activity in stimulation of gastrointestinal motility as will be described later in this specification. The compound (I) of the present invention can be formulated into a drug preparation for oral or parenteral administration after blended with pharmaceutically acceptable adjuvants. In the manufacture of oral-route preparations, the compound of the invention is blended with suitable additives, for example, vehicles such as lactose, mannitol, corn starch and crystalline cellulose; binders such as cellulose derivatives, gum arabic and gelatin; disintegrators such as carboxymethylcellulose calcium; and lubricants such as talc and magnesium stearate, and formed into tablets, powders, granules, capsules and the like. The obtained solid preparations may further be coated using coating bases such as hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, cellulose acetate phthalate and methacrylate copolymers and formed into enteric preparations. In the manufacture of parenteral preparations, the compounds of the invention may be combined, for example, with water, ethanol, glycerol or surfactants which are commonly used in this technical field and prepared into injection preparations; or combined with suppository bases to prepare suppositories. The amounts of administration of the compound (1) of the present invention vary depending on age, body weight, symptom of the disease, goal of the treatment, manner of administration, period of administration, etc. Generally, in the case of oral administration, the compound is administered in amounts of 1-2000 mg/day, preferably 10-300 mg/day, as divided in 1 to 3 times a day. Action Acceleration of Gastrointestinal Motility: The test was performed according to the method of Itoh et al. (Am. J. Dig. Dis. 22, 117-124, 1977). In detail, laparotomy was made to male dogs (body weight: 9-10 kg) under anesthesia with Nembutal (30 mg/kg, i.v.). Force transducers (F-121S, manufactured by Star Medical Co.) were implanted so that the contraction of circular muscle could be monitored on serosa of the gastric body, gastric antrum (about 3 cm proximal to the pylorus), duodenum and jejunum. In addition, a silicone tube was inserted from the right external carotid artery, and the tube was indwelled in the superior vena cava. The transducers and the silicone tube were subcutaneously exteriorized out of the body. The dog was submitted to the test with consciousness and without restraint after about 3 weeks from the operation. The contractile signals from each transducer were amplified with an amplifier (RTA-1200; manufactured by Nihon Kohden Co.), and recorded with a recording apparatus and a computer. The test compounds were dissolved in saline and intravenously administered (0.5 ml/kg) to the dogs through a silicone tube about 10 minutes after the termination of phase III contractions of interdigestive migrating contractions (IMC) in the antrum. Evaluation Method: Contractile signals from the antrum amplified in analog voltage were converted to digital signals, which were integrated to calculate the motor activity. The quantity of work which allows to sustain the maximum contraction in phase III contractions of IMC for 6 seconds was considered as 1 unit, and the motor index (units/30 min) in the period of 30 minutes after the administration of the test compound was obtained. The thus calculated motor index was compared with the motor index obtained after saline was administered. The results are shown in Table 1. Test Compounds Dose (mg/Kg) Motor Index (units/30min) Example 1 5 7.5 Example 6 5 6.1 Example 9 5 7.1 Example 11 5 10.9 Example 12 5 9.4 Example 14 5 6.6 Example 16 5 4.3 Saline - 0.1 Toxicity Test: Groups of 4 - 5 week old ICR mice, each group consisting of 6 mice, were provided for the test. The compounds obtained in the Examples were respectively suspended in 5% gum arabic and each suspension was orally administered to the mice at a dose of 1000 mg/kg. The mice were observed for 1 week. None of the mice died in any dosage groups. Examples The present invention will hereinafter be described in more detail by way of examples, which however should not be construed as limiting the invention thereto. Example 1: Trimethyl=[4-[[[2-[(1-methylamino-2-nitroethenyl)amino]ethyl]thio]methyl]-2-thiazolyl]methylammonium=iodide N-[2-[[[2-[dimethylamino)methyl-4-thiazolyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine (5 g) was dissolved in chloroform (50 ml). To this mixture, methyl iodide (2.19 g) was added dropwise while cooling on ice. After stirring for 24 hours at 0°C, the solvent was distilled off. The residue was purified by alumina column chromatography (chloroform - water) to obtain 6.8 g of the title compound. IR(KBr)cm -1 : 1380 MS(m/z) : 346(M-I) + NMR(DMSO-d 6 )δ : 2.55-2.90(5H,m), 3.15(9H,s), 3.33-3.47(2H,m), 3.97(2H,s), 4.94(2H,s), 6.50(1H,brd), 7.25(1H,brs), 7.80(1H,s), 9.99(1H,brd) Examples 2 to 18: The procedure of Example 1 was repeated, using starting materials which were suitably selected to obtain the compounds of Examples 2 to 18. Example 2: Trimethyl=[4-[[[2-[(1-methylamino-2-nitroethenyl)amino]ethyl]thio]methyl]-2-thiazolyl]methylammonium=bromide IR(nujol)cm -1 : 1380 MS(m/z) : 346(M-Br) + NMR(DMSO-d 6 )δ : 2.60-2.95(5H,m), 3.19(9H,s), 3.30-3.50(2H,m), 3.98(2H,s), 5.01(2H,s), 6.50(1H,brd), 7.36(1H,brs), 7.83(1H,s), 9.99(1H,brd) Example 3: Ethyl=dimethyl=[4-[[[2-[(1-methylamino-2-nitroethenyl)amino]ethyl]thio]methyl]-2-thiazolyl]methylammonium=bromide IR(KBr)cm -1 : 1385 MS(m/z) : 360(M-Br) + NMR(DMSO-d 6 )δ : 1.34(3H,t), 2.60-3.00(5H,m), 3.08(6H,s), 3.30-3.50(2H,m), 3.44(2H,q), 3.97(2H,s), 4.94(2H,s), 6.50(1H,brd), 7.31(1H,brs), 7.81(1H,s), 9.95(1H,brd) Example 4: Benzyl=dimethyl=[4-[[[2-[(1-methylamino-2-nitroethenyl)amino]ethyl]thio]methyl]-2-thiazolyl]methylammonium=chloride IR(KBr)cm -1 : 1385 MS(m/z) : 422(M-Cℓ) + NMR(DMSO-d 6 )δ : 2.60-2.95(5H,m), 3.04(6H,s), 3.30-3.60(2H,m), 4.01(2H,s), 4.75(2H,s), 4.99(2H,s), 6.50(1H,brd), 7.40-7.70(6H,m), 7.86(1H,s), 9.95(1H,brd) Example 5: Dimethyl=4-nitrobenzyl=[4-[[[2-[(1-methylamino-2-nitroethenyl)amino]ethyl]thio]methyl]-2-thiazolyl]methylammonium=bromide IR(KBr)cm -1 : 1385 MS(m/z) : 467(M-Br) + NMR(MeOH-d 4 )δ : 2.75-2.95(5H,m), 3.18(6H,s), 3.48(2H,t), 4.02(2H,s), 4.89(2H,s), 4.98(2H,s), 6.70(1H,brs), 7.73(1H,s), 8.01(2H,d), 8.38(2H,d) Example 6: Dimethyl=propargyl=[4-[[[2-[(1-ethylamino-2-nitroethenyl)amino]ethyl]thio]methyl]-2-thiazolyl]methylammonium=bromide IR(KBr)cm -1 : 2120, 1390 MS(m/z) : 384(M-Br) + NMR(DMSO-d 6 )δ : 1.09(3H,brs), 2.69(2H,brs), 3.19(6H,s), 3.05-3.55(4H,m), 3.94(2H,s), 4.08(1H,s), 4.51(2H,s), 5.03(2H,s), 6.48(1H,s), 7.31(1H,brs), 7.81(1H,s), 10.00(1H,brd) Example 7: Dimethyl=propargyl=[4-[[[2-[(3-methylureido)ethyl]thio]methyl]-2-thiazolyl]methylammonium=bromide IR(KBr)cm -1 : 2125, 1690 MS(m/z) : 327(M-Br) + NMR(DMSO-d 6 )δ : 2.50-2.56(5H,m), 3.12-3.40(2H,m), 3.21(6H,s), 3.92(2H,s), 4.12(1H,brs), 4.50(2H,d), 5.02(2H,s), 5.86(1H,brs), 6.06(1H,brs), 7.81(1H,s) Example 8: Trimethyl=[2-[[[2-[(1-methylamino-2-nitroethenyl)amino]ethyl]thio]methyl]-5-furanyl]methylammonium=iodide IR(KBr)cm -1 : 1385 MS(m/z) : 329(M-I) + NMR(DMSO-d 6 )δ : 2.60-2.90(5H,m), 3.04(9H,s), 3.30-3.48(2H,m), 3.89(2H,s), 4.61(2H,s), 6.46(1H,d), 6.48(1H,brs), 6.76(1H,d), 7.22(1H,brs), 9.98(1H,brd) Example 9: Dimethyl=propargyl=[2-[[[2-[(1-methylamino)-2-nitroethenyl)amino]ethyl]thio]methyl]-5-furanyl]methylammonium=bromide IR(KBr)cm -1 : 2125, 1385 MS(m/z) : 353(M-Br) + NMR(DMSO-d 6 )δ : 2.62-2.93(5H,m), 3.07(6H,s), 3.30-3.50(2H,m), 3.89(2H,s), 4.09(1H,t), 4.35(2H,d), 4.68(2H,s), 6.47(1H,d), 6.50(1H,brs), 6.79(1H,d), 7.32(1H,brd), 9.99(1H,brd) Example 10: Benzyl=dimethyl=[2-[[[2-[(1-methylamino-2-nitroethenyl)amino]ethyl]thio]methyl]-5-furanyl]methylammonium=bromide IR(KBr)cm -1 : 1385 MS(m/z) : 405(M-Br) + NMR(DMSO-d 6 )δ : 2.61-2.95(5H,m), 2.97(6H,s), 3.31-3.61(2H,m), 3.94(2H,s), 4.73(2H,s), 4.78(2H,s), 6.46(1H,brs), 6.48(1H,d), 6.86(1H,d), 7.42(1H,brs), 7.50-7.58(3H,m), 7.64-7.71(2H,m), 10.01(1H,brd) Example 11: Allyl=dimethyl=[4-[[[2-[(1-methylamino-2-nitroethenyl)amino]ethyl]thio]methyl]-2-thiazolyl]methylammonium=bromide IR(KBr)cm -1 : 1380 MS(m/z) : 372(M-Br) + NMR(DMSO-d 6 )δ : 2.55-3.00(5H,m), 3.09(6H,s), 3.33-3.55(2H,m), 3.98(2H,s), 4.10(2H,d), 4.95(2H,s), 5.62-5.73(2H,m), 6.02-6.23(1H,m), 6.46(1H,brd), 7.30(1H,brs), 7.81(1H,s), 9.99(1H,brd) Example 12: Dimethyl=propargyl=[4-[[[2-[(1-methylamino-2-nitroethenyl)amino]ethyl]thio]methyl]-2-thiazolyl]methylammonium=bromide IR(KBr)cm -1 : 2120, 1380 MS(m/z) : 370(M-Br) + NMR(DMSO-d 6 )δ : 2.53-2.92(5H,m), 3.19(6H,s), 3.39-3.60(2H,m), 3.97(2H,s), 4.12(1H,t), 4.47(2H,d), 5.00(2H,s), 6.49(1H,brd), 7.30(1H,brs), 7.82(1H,s), 9.99(1H,brd) Example 13: Dimethyl=3-methyl-2-butenyl=[4-[[[2-[(1-methylamino-2-nitroethenyl)amino]ethyl]thio]methyl]-2-thiazolyl]methylammonium=bromide IR(KBr)cm -1 : 1380 MS(m/z) : 400(M-Br) + NMR(DMSO-d 6 )δ : 1.78(3H,s), 1.85(3H,s), 2.60-2.90(5H,m), 3.03(6H, s), 3.30-3.50(2H,m), 3.98(2H,s), 4.06(2H,d), 4.92(2H,s), 5.50(1H,t), 6.44(1H,brs), 7.28(1H,s), 7.37(1H,brs), 9.98(1H,brd) Example 14: Benzyl=dimethyl=[4-[[[2-[(1-methylamino-2-nitroethenyl)amino]ethyl]thio]methyl]-2-thiazolyl]methylammonium=bromide IR(KBr)cm -1 : 1380 MS(m/z) : 422(M-Br) + NMR(DMSO-d 6 )δ : 2.60-2.90(5H,m), 3.06(6H,s), 3.37-3.55(2H,m), 4.01(2H,s), 4.78(2H,s), 5.01(2H,s), 6.48(1H,brd), 7.37(1H,brs), 7.49-7.57(3H,m), 7.67-7.70(2H,m), 7.86(1H,s), 9.95(1H,brd) Example 15: Dimethyl=propargyl=[3-[[[2-[(1-methylamino-2-nitroethenyl)amino]ethyl]thio]methyl]benzylammonium=bromide IR(KBr)cm -1 : 2120, 1385 MS(m/z) : 363(M-Br) + NMR(DMSO-d 6 )δ : 2.50-2.90(5H,m), 3.05(6H,s), 3.25-3.45(2H,m), 3.86(2H,s), 4.15(1H,t), 4.30(2H,d), 4.59(2H,s), 6.46(1H,brs), 7.27(1H,brs), 7.44-7.54(4H,m), 9.97(1H,brd) Example 16: Dimethyl=propargyl=[2-[[[2-[(1-methylamino-2-nitroethenyl)amino]ethyl]thio]methyl]-5-thienyl]methylammonium=bromide IR(KBr)cm -1 : 2110, 1380 MS(m/z) : 369(M-Br) + NMR(DMSO-d 6 )δ : 2.60-2.95(5H,m), 3.11(6H,s), 3.30-3.50(2H,m), 4.12(2H,s), 4.15(1H,s), 4.36(2H,s), 4.85(2H,s), 6.46(1H,s), 7.12(1H,d), 7.28(1H,d), 7.35(1H,brs), 10.00(1H,brd) Example 17: Cinnamyl=dimethyl=[4-[[[2-[(1-methylamino-2-nitroethenyl)amino]ethyl]thio]methyl]-2-thiazolyl]methylammonium=bromide IR(KBr)cm -1 : 1380 MS(m/z) : 448(M-Br) + NMR(DMSO-d 6 )δ : 2.57-2.85(5H,m), 3.13(6H,s), 3.20-3.50(2H,m), 4.00(2H,s), 4.24(2H,d), 4.98(2H,s), 6.44(1H,brs), 6.56(1H,dt), 6.95(1H,d), 7.25(1H,brs), 7.36-7.63(5H,m), 7.82(1H,s), 9.97(1H,brd) Example 18: Trimethyl=[4-[[[2-[(1-methylamino-2-nitroethenyl)amino]ethyl]thio]methyl]-2-thiazolyl]methylammonium=p-toluenesulfonato IR(KBr)cm -1 : 1390 MS(m/z) : 346(M-C 7 H 7 SO 3 ) + NMR(DMSO-d 6 )δ : 2.29(3H,s), 2.60-2.90(5H,m), 3.16(9H,s), 3.42(2H,m), 3.96(2H,s), 4.95(2H,s), 6.50(1H,brd), 7.13(2H,d), 7.32(1H,brs), 7.51(2H,d), 7.80(1H,s), 10.00(1H,brd) Example 19: Trimethyl=[4-[[[2-[(1-methylamino-2-nitroethenyl)amino]ethyl]thio]methyl]-2-thiazolyl]methylammonium= chloride Method A : The compound (20g) obtained in Example 1 was allowed to pass through an anion exchange resin column (IRA-900, Cl-type), and eluted with purified water. The solvent in the eluted fraction was distilled off under reduced pressure to obtain 14.6 g of the target compound. IR(nujol)cm -1 : 1380 MS(m/z) : 346(M-Cℓ) + NMR(DMSO-d 6 )δ : 2.51-2.91(5H,m), 3.21(9H,s), 3.30-3.50(2H,m), 3.99(2H,s), 5.07(2H,s), 6.50(1H,brd), 7.80(1H,brs), 7.86(1H,s), 9.99(1H,brd) Method B : (1) N-[2-[[(2-hydroxymethyl-4-thiazolyl)methyl]thio]ethyl]-N'-methyl-2-nitrol-1,1-ethenediamine Under stream of argon, 1-methylamino-1-methylthio-2-nitroethene (16.6 g) was dissolved in absolute methanol (300 ml), to which 2-aminoethanethiol (8.64 g) was added. The obtained mixture was stirred for 30 minutes at room temperature, and the solvent was distilled off under reduced pressure. The residue was dissolved in an aqueous KOH solution (1.1 N, 200 ml). This aqueous solution was added dropwise to a mixture of 2-benzoyloxymethyl-4-chloromethylthiazol (25.0 g) and methanol (250 g) while cooling on ice. The resulting mixture was stirred for 1 hour in an ice bath, and further for 4 hours at room temperature. Subsequently, the solvent was distilled off under reduced pressure. The residue was purified by alumina column chromatography (chloroform - methanol), recrystallized from methanol-ethyl acetate to obtain 12.4 g of the title compound. m.p. 131.3-132.3°C IR(KBr)cm -1 : 3165, 1625, 1560, 1375 MS(m/z) : 305(MH + ) NMR(DMSO-d 6 )δ : 2.70(3H,brd), 2.83(2H,brd), 3.36(2H,brd), 3.84(2H,s), 4.69(2H,d), 6.01(1H,t), 6.44(1H,brd), 7.22(1H,brd), 7.39(1H,s), 10.04(1H,brd) (2) N-[2-[(2-chloromethyl-4-thiazolyl)methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine N-[2-[[(2-hydroxymethyl-4-thiazolyl)methyl]thio]ethyl]N'-methyl-2-nitro-1,1-ethenediamine (1 g) obtained in (1) above was added to phosphorus oxychloride (15 ml), and the mixture was stirred for 21 hours at room temperature. The reaction mixture was concentrated under reduced pressure. The residue was combined with ice-water, and then extracted with ethyl acetate. The extract was washed with saturated NaCl solution, followed by drying over magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform - methanol) to obtain 420 mg of the title compound. IR(CHCℓ 3 )cm -1 : 1610, 1570, 1385 MS(m/z) : 323(MH + ) NMR(DMSO-d 6 )δ : 2.75(2H,t), 2.78(3H,d), 3.38(2H,q), 3.88(2H,s), 5.00(2H,s), 6.43(1H,s), 7.24(1H,brd), 7.51(1H,s), 10.05(1H,brd) (3) Trimethyl=[4-[[[2-[(1-methylamino-2-nitroethenyl)amino]ethyl]thio]methyl]-2-thiazolyl]methylammonium=chloride N-[2-[[(2-chloromethyl-4-thiazolyl)methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine (394 mg) obtained in (2) above was dissolved in methanol (10 ml), into which trimethylamine was blown while cooling the mixture on ice. The resulting mixture was stirred overnight at room temperature, and the solvent was distilled off under reduced pressure. The residue was purified by alumina column chromatography (chloroform - methanol) to obtain 250 mg of the title compound. IR(nujol)cm -1 : 1380 MS(m/z) : 346(M-Cℓ) + NMR(DMSO-d 6 )δ : 2.51-2.91(5H,m), 3.21(9H,s), 3.30-3.50(2H,m), 3.99(2H,s), 5.07(2H,s), 6.50(1H,brd), 7.80(1H,brs), 7.86(1H,s), 9.99(1H,brd) Formulation Example 1: Compound of Example 1 20 g Lactose 315 g Corn starch 125 g Crystalline cellulose 25 g The above ingredients were blended into a uniform mixture, to which 200 ml of 7.5% aqueous hydroxypropylcellulose solution was added, and then passed an extruder equipped with a screen of 0.5 mm in diameter to prepare granules. Immediately thereafter, the granules were rounded with a marumerizer and dried to obtain a granule preparation. Formulation Example 2: Compound of Example 11 20 g Lactose 100 g Corn starch 36 g Crystalline cellulose 30 g Carboxymethylcellulose calcium 10 g Magnesium stearate 4 g The above ingredients were blended into a uniform mixture, and prepared into tablets each weighing 200 mg with a single-shot tableting machine equipped with a pestle having a diameter of 7.5 mm. Formulation Example 3: Compound of Example 12 100 mg Sodium acetate 2 mg Acetic acid (for adjusting pH to 5.8) suitable amount Purified water suitable amount Total: 10 ml/vial The above formulation was prepared into an injection preparation by a method known per se . Since the compounds according to the present invention have activity of accelerating the gastrointestinal contraction or of improving the gastrointestinal motility remarkably as well as high safety, they have utility in the medical field of treating gastrointestinal disorders.

Claims: Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IE, IT, LI, LU, MC, NL, PT, SE A quaternary ammonium salt represented by the following formula (I): wherein R 1 and R 2 represent alkyl groups having 1 to 5 carbon atoms which may be the same or different from each other; R 3 represents hydrogen, alkyl having 1 to 5 carbon atoms, phenyl, benzyl, or -COOR 4 (wherein R 4 represents alkyl having 1 to 5 carbon atoms); A represents alkyl having 1 to 5 carbon atoms, alkenyl having 2 to 5 carbon atoms, alkynyl having 2 to 5 carbon atoms, -(CH 2 ) p -COOR 5 (wherein R 5 represents hydrogen or alkyl having 1 to 5 carbon atoms, and p represents an integer of from 1 to 5), (wherein R 6 represents hydrogen, hydroxyl, nitro, alkyl having 1 to 5 carbon atoms, -COOR 5 , or -SO 3 R 5 ); Q - represents a counter anion of quaternary ammonium salt; X represents Y represents methylene, oxygen or sulfur; Z represents (wherein R 7 and R 8 are the same or different from each other and independently represent hydrogen, halogen, nitro, alkyl having 1 to 5 carbon atoms, or lower alkoxyl, and R 9 represents alkyl having 1 to 5 carbon atoms, or phenyl); l and m represent each an integer of 1 or 2; and n represents an integer of from 1 to 3. The quaternary ammonium salt of claim 1 for use as a medicine. The quaternary ammonium salt of claim 1 for use as a gastroprokinetic agent. A compound represented by the following formula (IX): wherein R 3 represents hydrogen, alkyl having 1 to 5 carbon atoms, phenyl, benzyl, or -COOR 6 (wherein R 6 represents alkyl having 1 to 5 carbon atoms); D represents halogen or an active ester residue; X represents Y represents methylene, oxygen or sulfur; Z represents (wherein R 7 and R 8 are the same or different from each other and independently represent hydrogen, halogen, nitro, alkyl having 1 to 5 carbon atoms, or lower alkoxyl, and R 9 represents alkyl having 1 to 5 carbon atoms, or phenyl); l and m represent each an integer of 1 or 2; and n represents an integer of 1 to 3. Claims for the following Contracting States : ES, GR A quaternary ammonium salt represented by the following formula (I): wherein R 1 and R 2 represent alkyl groups having 1 to 5 carbon atoms which may be the same or different from each other; R 3 represents hydrogen, alkyl having 1 to 5 carbon atoms, phenyl, benzyl, or -COOR 4 (wherein R 4 represents alkyl having 1 to 5 carbon atoms); A represents alkyl having 1 to 5 carbon atoms, alkenyl having 2 to 5 carbon atoms, alkynyl having 2 to 5 carbon atoms, -(CH 2 ) p -COOR 5 (wherein R 5 represents hydrogen or alkyl having 1 to 5 carbon atoms, and p represents an integer of from 1 to 5), (wherein R 6 represents hydrogen, hydroxyl, nitro, alkyl having 1 to 5 carbon atoms, -COOR 5 , or -SO 3 R 5 ); Q - represents a counter anion of quaternary ammonium salt; X represents Y represents methylene, oxygen or sulfur; Z represents (wherein R 7 and R 8 are the same or different from each other and independently represent hydrogen, halogen, nitro, alkyl having 1 to 5 carbon atoms, or lower alkoxyl, and R 9 represents alkyl having 1 to 5 carbon atoms, or phenyl); l and m represent each an integer of 1 or 2; and n represents an integer of from 1 to 3. The quaternary ammonium salt of claim 1 for use as a medicine. The quaternary ammonium salt of claim 1 for use as a gastroprokinetic agent. A compound represented by the following formula (IX): wherein R 3 represents hydrogen, alkyl having 1 to 5 carbon atoms, phenyl, benzyl, or -COOR 6 (wherein R 6 represents alkyl having 1 to 5 carbon atoms); D represents halogen or an active ester residue; X represents Y represents methylene, oxygen or sulfur; Z represents (wherein R 7 and R 8 are the same or different from each other and independently represent hydrogen, halogen, nitro, alkyl having 1 to 5 carbon atoms, or lower alkoxyl, and R 9 represents alkyl having 1 to 5 carbon atoms, or phenyl); l and m represent each an integer of 1 or 2; and n represents an integer of 1 to 3. A process for the production of a quarternary ammonium salt represented by the following formula (I): wherein R 1 and R 2 represent alkyl groups having 1 to 5 carbon atoms which may be the same or different from each other; R 3 represents hydrogen, alkyl having 1 to 5 carbon atoms, phenyl, benzyl, or -COOR 4 (wherein R 4 represents alkyl having 1 to 5 carbon atoms); A represents alkyl having 1 to 5 carbon atoms, alkenyl having 2 to 5 carbon atoms, alkynyl having 2 to 5 carbon atoms, -(CH 2 ) p -COOR 5 (wherein R 5 represents hydrogen or alkyl having 1 to 5 carbon atoms, and p represents an integer of from 1 to 5), (wherein R 6 represents hydrogen, hydroxyl, nitro, alkyl having 1 to 5 carbon atoms, -COOR 5 , or -SO 3 R 5 ); Q - represents a counter anion of quaternary ammonium salt; X represents Y represents methylene, oxygen or sulfur; Z represents (wherein R 7 and R 8 are the same or different from each other and independently represent hydrogen, halogen, nitro, alkyl having 1 to 5 carbon atoms, or lower alkoxyl, and R 9 represents alkyl having 1 to 5 carbon atoms, or phenyl); l and m represent each an integer of 1 or 2; and n represents an integer of from 1 to 3. characterized in that a compound of formula (II) is reacted with a compound of formula (III) as shown in the following reaction scheme: (wherein R 1 , R 2 , R 3 , A, Q, X, Y, Z, l, m and n have the same meaning as defined hereinbefore) in a temperature range of 0°C to reflux temperature. The process of claim 5, characterized in that the reaction is carried out in an inert solvent, such as methanol ethanol, dichloromethane, chloroform, ethylacetate, dimethylformamide, dimethylsulfoxide and water. The process of claim 5 or 6, characterized in that the compounds (II) and (III) are used in an equimolar amount. A process for the production of a compound represented by the following formula (IX): wherein R 3 represents hydrogen, alkyl having 1 to 5 carbon atoms, phenyl, benzyl, or -COOR 6 (wherein R 6 represents alkyl having 1 to 5 carbon atoms); D represents halogen or an active ester residue; X represents Y represents methylene, oxygen or sulfur; Z represents (wherein R 7 and R 6 are the same or different from each other and independently represent hydrogen, halogen, nitro, alkyl having 1 to 5 carbon atoms, or lower alkoxyl, and R 9 represents alkyl having 1 to 5 carbon atoms, or phenyl); l and m represent each an integer of 1 or 2; and n represents an integer of 1 to 3 comprising the following steps: i) reacting a compound of the formula (IV) with a compound of the formula (V) to give a compound of formula (VI): (wherein R 3 , X, Y, Z, l, m and n have the same meaning as defined hereinbefore), ii) reacting the obtained compound of formula (VI) with a compound of formula (VII) in the presence of an alkali to give a compound of formula (VIII): (wherein E represents a protective group for an alcohol and B represents a halogen atom), and iii) adding an agent for halogenation of an acid halide to give the desired compound of formula (IX): The process of claim 8 characterized in that E in formula (VII) represents a benzoyl or acetyl group. The process of claims 8 or 9 characterized in that process step i) is carried out in an anhydrous organic solvent. The process of claims 8 to 10 characterized in that the reaction temperature is within the range of 0°C to the boiling point of the reaction mixture. The process of claims 8 to 11 characterized in that the agent for halogenation used in process step iii) is phosphorus oxychloride. The process of claims 8 to 12 characterized in that the acid halide used in process step iii) is selected from methanesulfonic acid chloride and/or toluene sulphonic acid chloride. A process for the production of the compound of formula (I) as defined in claims 1 and 5 characterized in that a compound of formula (IX) as defined in claim 4 is reacted with an amine compound (X): (wherein R 1 , R 2 and A are defined as in claims 1 and 5).

Inventors: ISHII KATSUYUKI, KITAGAWA OSAMU, NIWA SEIICHI, SEIKI MASAO, UEKI SIGERU, ISHII, KATSUYUKI, KITAGAWA, OSAMU, NIWA, SEIICHI, SEIKI, MASAO, UEKI, SIGERU, ISHII, KATSUYUKI, ZERIA PHARMACEUTICAL CO., LTD., KITAGAWA, OSAMU, ZERIA PHARM. CO.,LTD. CENT. LAB., NIWA, SEIICHI, ZERIA PHARM. CO LTD. CENTRES LAB., SEIKI, MASAO, ZERIA PHARM. CO LTD CENT. RES. LAB., UEKI, SIGERU, ZERIA PHARM. CO LTD CENTR.RES.LAB.
Applicants: ZERIA PHARM CO LTD, ZERIA PHARMACEUTICAL CO., LTD.
Application year: 1993
Main classification: C07C211
IPC codes: C07C323, C07D277, C07D333, C07D307